Sage Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10
- Market Cap
- $495.1M
- Website
- http://www.sagerx.com
- Introduction
Sage Potash Corp is engaged in the acquisition, exploration, and development of mineral properties. Its principal business activity is the acquisition, exploration, and development of potash mineral properties. It holds interest in Sage Plain Potash property. The projects of the company include Sage Potash and Sage Lithium.
WHO approves MVA-BN as first prequalified vaccine against mpox
WHO approves MVA-BN vaccine as first mpox vaccine for prequalification, aiming to facilitate timely access and reduce transmission. The vaccine, administered in 2 doses 4 weeks apart, can be stored at 2–8°C for up to 8 weeks and is recommended for high-risk individuals, including 'off-label' use in children and pregnant women. Single-dose use is advised in supply-constrained situations, with estimated 76% effectiveness pre-exposure and 82% with 2 doses.
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
Sage Therapeutics and Biogen announce topline results from Phase 2 KINETIC 2 study of SAGE-324 (BIIB124) for essential tremor, showing no statistically significant dose-response relationship on primary endpoint. No further clinical development planned for SAGE-324 in essential tremor.
© Copyright 2024. All Rights Reserved by MedPath